(via NewsDirect)
Kohlhof explained that celiac disease is a severe autoimmune disorder affecting around 1% of the global population, predominantly females. Unlike gluten intolerance, celiac disease involves an immune reaction to gluten, leading to gut inflammation and destruction. The only current treatment is a gluten-free diet, which is not effective for all patients.
Kohlhof elaborated on the disease's scientific background, highlighting its genetic association with specific HLA genotypes (HLA-DQ2 and HLA-DQ8). She explained that celiac disease is triggered by the immune system's reaction to deaminated gluten peptides, causing inflammation and damage to the gut lining.
Kohlhof detailed the successful completion of a Phase 1b study in celiac patients, which demonstrated the drug’s safety, good pharmacokinetic properties, and positive effects on symptoms, biomarkers, gut histology, and nutrient uptake during a gluten challenge. The study confirmed the potential of IMU-856 in treating celiac disease, and further exploration of its mode of action is ongoing.
Contact Details
+1 604-688-8158
NA-editorial@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source